Slingshot members are tracking this event:

Sangamo Therapeutics (SMGO) earns FDA Fast Track Designation for SB-318 And SB-913 in treatment of Mucopolysaccharidosis (MPS) I and II

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
SGMO Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 13, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda Fast Track Designation, Sb-318, Sb-913, Mucopolysaccharidosis